AstraZeneca (LON:AZN) Earns Hold Rating from Jefferies Financial Group

Jefferies Financial Group restated their hold rating on shares of AstraZeneca (LON:AZN) in a report issued on Tuesday morning, MarketBeat Ratings reports. They currently have a £113 ($143.62) target price on the biopharmaceutical company’s stock.

A number of other analysts have also weighed in on the stock. Deutsche Bank Aktiengesellschaft reissued a hold rating and issued a £105 ($133.45) price target on shares of AstraZeneca in a report on Tuesday, April 23rd. UBS Group reduced their price target on shares of AstraZeneca from £107 ($135.99) to GBX 9,900 ($125.83) and set a sell rating on the stock in a research report on Monday, February 12th. BMO Capital Markets reiterated an outperform rating on shares of AstraZeneca in a report on Monday, February 12th. Barclays restated an overweight rating and issued a £125 ($158.87) price target on shares of AstraZeneca in a report on Monday, April 8th. Finally, Berenberg Bank increased their price target on AstraZeneca from £120 ($152.52) to £130 ($165.23) and gave the company a buy rating in a research report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and an average price target of £118 ($149.97).

AstraZeneca Trading Down 0.9 %

AZN stock opened at £122.96 ($156.28) on Tuesday. AstraZeneca has a 1-year low of GBX 9,461 ($120.25) and a 1-year high of £124.88 ($158.72). The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 92.51. The business’s 50 day moving average is £113.69 and its 200-day moving average is £106.82. The firm has a market cap of £190.59 billion, a P/E ratio of 3,842.50, a P/E/G ratio of 0.95 and a beta of 0.16.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.